(PDF) P2.04-10 Early Monitoring of Blood Biomarkers to

P2.04-10 Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1234

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P2.04-11 an IL-8/IFN-gammma/NLR Plasma Score to Predict Nivolumab Efficacy in Patients With NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated With Nivolumab

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.04-12 a Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.

Journal of Thoracic Oncology

Respiratory Medicine

English

182P: Intracranial Response to Nivolumab in NSCLC Patients With Untreated or Progressing CNS Metastases

Journal of Thoracic Oncology

Respiratory Medicine

English

Nivolumab for NSCLC in Japanese Patients: Similar Benefits, but Beware of Pneumonitis

Cancer Research

English

P3.01-74 Clinical and Radiological Predictors of Efficacy to Nivolumab in NSCLC: A Multi-Institutional, Retrospective Cohort Study.

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.04-19 Correlation of Clinicopathological Characteristics With Tumor Mutation Burden in Chinese Patients With NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 Mut/Mb): Results From CheckMate 227

Journal of Thoracic Oncology

Respiratory Medicine

English

Emergence of Digital Biomarkers to Predict and Modify Treatment Efficacy: Machine Learning Study

English